

# SPARK EUROPE WEBINAR SERIES 2025

Wednesdays  
at 4 pm CET

SPARK Europe  
Education

## How and why to work with CRO's – an introduction by Charles River



Online via **Zoom**  
Please register [here!](#)

**June 4, 2025 | 4 – 5 pm (CET) | Online Webinar**

In this online SPARK Europe Webinar Series organised by SPARK Finland Dale Mitchell and Sarah Gould will share their insights on how early-stage academic projects and startups may benefit from working with CRO's.



**DALE MITCHELL**  
*Senior Director Small Molecule Drug Discovery*  
**Charles River Laboratories**

Dale has worked for Charles River and legacy companies since 2000 and has 37 years' experience in the pharmaceutical and agrochemical industries. Dale has led a wide range of collaborative programs in areas such as inflammation, oncology, anti-infectives, neurodegeneration and PET imaging. In his current role, Dale provides strategic oversight on integrated drug discovery programs, working closely with multi-disciplinary project teams and partners to generate hit compounds, deliver lead series and identify pre-clinical candidates.



**SARAH GOULD**  
*Director Senior Principle Scientific Advisor*  
**Charles River Laboratories**

Senior regulatory pharmaco-toxicologist and program manager with extensive experience (18 years) working for blue-chip, international pharmaceutical companies. I have a proven track record of effective delivery, bringing small and large molecule projects forward to clear decision milestones, submissions to, and interactions with health authorities up to licence (eg IND's, IMPD's, CTD's etc), with full knowledge of GLP/GXP standards and regulatory guidelines (ICH, CHMP, FDA, WHO).

*SPARK is an initiative created at Stanford University, to overcome challenges associated with translation of academic discoveries.*

In unforeseen cases, the organizers may change and update topics and speakers.

SPARK  
FINLAND

SPARK  
TEL AVIV

SPARK  
PARIS

SPARK  
POLAND

SPARK  
NORWAY

SPARK FLI

SPARK  
BIH

CHARITÉ  
Innovation  
Der Technologietransfer von Charité und BIH